Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tilpisertib fosmecarbil
- Development stage
- Phase 2
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tilpisertib fosmecarbil is an orally administered small molecule drug under development by Gilead Sciences for the treatment of ulcerative colitis and other inflammatory bowel diseases. It acts as an inhibitor of tumor progression locus 2 (TPL2), also known as mitogen-activated protein kinase kinase kinase 8 (MAP3K8). By inhibiting TPL2, tilpisertib fosmecarbil is expected to modulate inflammatory signaling pathways, potentially reducing inflammation in the colon. The drug is currently in Phase II clinical trials for patients with moderate to severe ulcerative colitis[1][2][3][4][6].
02
Targets
MAP3K8
Beyond the preview
Go deeper on tilpisertib fosmecarbil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tilpisertib fosmecarbil.